Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
OBJECTIVE
To determine the in vitro antifungal activity of voriconazole, a new triazole, compared with other polyene and imidazole antifungal agents against corneal isolates of Scedosporium apiospermum.


METHODS
Macro-broth dilution susceptibility testing was performed on five isolates of S. apiospermum obtained from patients with keratomycosis to determine the minimal inhibitory concentrations (MICs) for amphotericin B, natamycin, ketoconazole, itraconazole, and voriconazole. The use of oral voriconazole in the management of a patient with posttraumatic S. apiospermum keratitis is described.


RESULTS
S. apiospermum is generally resistant to commonly used topical ophthalmic antifungal agents. The MIC of voriconazole was 0.5 microg/mL, a concentration lower than that of other imidazoles.


CONCLUSIONS
Voriconazole has promising activity against and may prove useful in the management of fungal keratitis.
Shah
Kekul B
KB
Sid W. Richardson Ocular Microbiology Laboratory, Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
Wu
Tzu G
TG
Wilhelmus
Kirk R
KR
Jones
Dan B
DB
D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003315:Cornea / Q000382:microbiology*; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D007634:Keratitis / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008271:Mycetoma / Q000188:drug therapy / Q000382:microbiology; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D021681:Scedosporium / Q000187:drug effects* / Q000302:isolation & purification; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole